Hyperthermic isolation limb perfusion with TNFα in the treatment of in-transit melanoma metastasis

In Vivo

Volumn 20, Issue 6 A, 2006, Pages 739-742

  Di Filippo, Franco ^a   Rossi, Carlo Riccardo ^b   Santinami, Mario ^c   Cavaliere, Francesco ^d   Garinei, Rosa ^a   Anzà, Michele ^a   Perri, Pasquale ^a   Botti, Claudio ^a   Di Angelo, Piera ^a   Pasqualoni, Rossella ^a   Di Filippo, Simona ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Melanoma; Regional perfusion; TNF

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARM BLOOD VESSEL; ARTICLE; AXILLARY ARTERY; AXILLARY VEIN; BLOOD TOXICITY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EXTRACORPOREAL CIRCULATION; FEMALE; HUMAN; HYPERTHERMIC THERAPY; ILIAC ARTERY; ILIAC VEIN; INOPERABLE CANCER; ITALY; LEG BLOOD VESSEL; LIMB DISEASE; LIMB PERFUSION; LOW DRUG DOSE; LUNG TOXICITY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; OPTIMAL DRUG DOSE; PHASE 2 CLINICAL TRIAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; SYSTEMIC DISEASE;

EID: 33846077186     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Di Filippo F, Calabro A, Giannarelli D, Carlini S, Cavaliere F, Moscarelli F and Cavaliere R: Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 63: 2551-2561, 1989.
2. Lienard D, Eggermont AM, Koops HS, Kroon B, Towse G, Hiemstra S, Schmitz P, Clarke J, Steinmann G, Rosenkaimer F and Lejeune FJ: Isolated limb perfusion with tumor necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 9(5): 491-502, 1999.
3. Di Filippo F, Rossi CR, Garinei R, Anzà M, Cavaliere F, Botti C, Perri P, Di Filippo S, Di Angelo P, Principi F and Laurenzi L: Hyperthermic antiblastic perfusion with TNFα and melphalan in stage III limb melanoma patients: a phase I-II SITILO study. J Exp Clin Cancer Res 22(4): 97-101, 2003.
4. Casara D, Rubello D, Pilati PP, Scalerta R, Foletto M and Rossi CR: Optimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand held gamma probe and 99mTc-HAS. Nucl Med Commun 25(1): 61-66, 2004.
5. Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA and Olthuis GA: Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reaction. Eur J Cancer Clin Oncol 18(10): 905-910, 1982.
6. Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, Sussman JJ, Kraybill WG, Kane JM 3rd, Alexander HR, Lee JE, Mansfield PF, Pingpank JF, Wincherster DJ, White RL Jr, Chadaram V, Herndon JE 2nd, Fraker DL and Tyler DS: Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 24(25): 4196-4201, 2006.
7. Fraker D, Alexander H and Ross M: A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma (IFN). Ann Surg Oncol 9: S8, 2002.
8. Rossi CR, Foletto M, Mocellin S, Pilati PL and Lise M: Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-[alpha] and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 11(2): 173-177, 2004.
9. Eggermont AM, de Wilt JH and ten Hagen TL: Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 4: 429-437, 2003.
10. de Wilt JH, Manusama ER, van Tiel ST, van Ijken MG, ten Hagen TL and Eggermont AM: Prerequisites for effective isolated limb perfusion using Tumor Necros Factor Alpha and Melphalan in rats. BR J Cancer 8: 161-166, 1999.
11. de Wilt JH, ten Hagen TL, de Boech G, van Tiel St, de Bruijn EA and Eggermont AM: Tumour necrosis factor alpha increases meiphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82: 1000-1003, 2000.